Page 63 - 2020_02-Haematologica-web

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT
and EBMT (JACIE)
Ibrahim Yakoub-Agha,1 Christian Chabannon,2 Peter Bader,3 Grzegorz W. Basak,4 Halvard Bonig,5 Fabio Ciceri,6 Selim Corbacioglu,7 Rafael F. Duarte,8 Hermann Einsele,9 Michael Hudecek,9 Marie José Kersten,10 Ulrike Köhl,11 Jürgen Kuball,12 Stephan Mielke,13 Mohamad Mohty,14 John Murray,15 Arnon Nagler,16 Stephen Robinson,17 Riccardo Saccardi,18 Fermin Sanchez-Guijo,19 John A. Snowden,20 Micha Srour,21 Jan Styczynski,22 Alvaro Urbano-Ispizua,23 Patrick J. Hayden24 and Nicolaus Kröger25
1CHU de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France; 2Institut Paoli- Calmettes & Module Biothérapies, INSERM CBT-1409, Centre d’Investigations Cliniques de Marseille, Marseille, France; 3Clinic for Children and Adolescents, University Children's Hospital, Frankfurt, Germany; 4Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland; 5Institute for Transfusion Medicine and Immunohematology of Goethe University and German Red Cross Blood Service, Frankfurt, Germany; 6Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy; 7Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital of Regensburg, Regensburg, Germany; 8Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; 9Medizinische Klinikund Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; 10Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, the Netherlands; 11Fraunhofer Institute for Cellular Therapeutics and Immunology (IZI) and Institute of Clinical Immunology, University of Leipzig, Leipzig as well as Institute for Cellular Therapeutics, Hannover Medical School, Hannover, Germany; 12Department of Hematology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands; 13Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet and University Hospital, Stockholm, Sweden; 14Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRS 938, Paris, France; 15Christie Hospital NHS Trust, Manchester, UK; 16The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 17University Hospitals Bristol NHS Foundation Trust, Bristol, UK; 18Hematology Department, Careggi University Hospital, Florence, Italy; 19IBSAL-Hospital Universitario de Salamanca, CIC, Universidad de Salamanca, Salamanca, Spain; 20Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; 21Service des Maladies du Sang, CHU de Lille, Lille, France; 22Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland; 23Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain; 24Department. of Hematology, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland and 25Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
ABSTRACT
Chimeric antigen receptor (CAR) T cells are a novel class of anti-can- cer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagen- lecleucel (KymriahTM) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient
Ferrata Storti Foundation
Haematologica 2018 Volume 105(2):297-316
Correspondence:
PATRICK J. HAYDEN
phayden@stjames.ie
Received: June 16, 2019. Accepted: November 19, 2019. Pre-published: November 21, 2019.
doi:10.3324/haematol.2019.229781
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/2/297
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
haematologica | 2020; 105(2)
297
GUIDELINE ARTICLE